Identification and Characterization of a Novel IL-4 Receptor α Chain (IL-4Rα) Antagonist to Inhibit IL-4 Signalling

Cellular Physiology and Biochemistry

Volumn 36, Issue 3, 2015, Pages 831-842

  Ahmed, Nayyar ^a   Dhanapala, Pathum ^a,b   Suphioglu, Cenk ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b CSIRO   (Australia)

Author keywords

Allergy; ELISA; HEK Blue cell line; IgE; IL 4 receptor; IL 4 signalling pathway; Phage display

Indexed keywords

ALKALINE PHOSPHATASE; INTERLEUKIN 4 RECEPTOR ALPHA ANTAGONIST; PROTEIN INHIBITOR; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIALLERGIC AGENT; IL4 PROTEIN, HUMAN; IL4R PROTEIN, HUMAN; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; ISOPROTEIN; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING;

ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG IDENTIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; MOLECULAR CLONING; PEPTIDE LIBRARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOASSAY; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; METABOLISM; SYNTHESIS;

ALKALINE PHOSPHATASE; ANTI-ALLERGIC AGENTS; BIOLOGICAL ASSAY; CELL LINE; COLORIMETRY; GENE EXPRESSION; HEK293 CELLS; HUMANS; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION;

EID: 84930526104     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430259     Document Type: Article

References (56)

1. Graham-Rowe D: Lifestyle: When allergies go west. Nature 2011;479:S2-S4.
2. Duksal F, Akcay A, Becerir T, Ergin A, Becerir C, Guler N: Rising trend of allergic rhinitis prevalence among Turkish schoolchildren. Int J Pediatr Otorhinolaryngol 2013;77:1434-1439.
3. Banac S, Rozmanic V, Manestar K, Korotaj-Rozmanic Z, Lah-Tomulic K, Vidovic I, Serer M, Svraka N, Petric T: Rising trends in the prevalence of asthma and allergic diseases among school children in the north-west coastal part of Croatia. J Asthma 2013;50:810-814.
4. Wong GW, Leung TF, Ko FW: Changing prevalence of allergic diseases in the Asia-pacific region. Allergy Asthma Immunol Res 2013;5:251-257.
5. Koplin JJ, Allen KJ, Gurrin LC, Peters RL, Lowe AJ, Tang ML, Dharmage SC (HealthNuts Study Team): The Impact of Family History of Allergy on Risk of Food Allergy: A Population-Based Study of Infants. Int J Environ Res Public Health 2013;10:5364-5377.
6. Mallen CD, Mottram S, Wynne-Jones G, Thomas E: Birth-related exposures and asthma and allergy in adulthood: a population-based cross-sectional study of young adults in North Staffordshire. J Asthma 2008;45:309-312.
7. Prescott S, Allen KJ: Food allergy: riding the second wave of the allergy epidemic. Pediatr Allergy Immunol 2011;22:155-160.
8. Ngoc PL, Gold DR, Tzianabos AO, Weiss ST, Celedon JC: Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol 2005;5:161-166.
9. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD: lnterleukin-4 and interleukin-13 signalling connections maps. Science 2003;300:1527-1528.
10. Venkayya R, Lam M, Willkom M, Griinig G, Corry DB, Erle DJ: The Th2 lymphocyte products lL-4 and lL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am J Respir Cell Mol Biol 2002;26:202-208.
11. Chomarat P, Banchereau J: lnterleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev lmmunol 1998;17:1-52.
12. Schnyder B, Lugli S, Feng N, Etter H, Lutz RA, Ryffel B, Sugamura K, Wunderli-Allenspach H, Moser R: lnterleukin-4 (lL-4) and lL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain. Blood 1996;87:4286-4295.
13. Deo SS, Mistry KJ, Kakade AM, Niphadkar PV: Role played by Th2 type cytokines in lgE mediated allergy and asthma. Lung lndia 2010;27:66-71.
14. Williams CM, Rahman S, Hubeau C, Ma HL: Cytokine pathways in allergic disease. Toxicol Pathol 2012;40:205-215.
15. Georas SN, Guo J, De Fanis U, Casolaro V: T-helper cell type-2 regulation in allergic disease. Eur Respir J 2005;26:1119-1137.
16. Webb DC, Cai Y, Matthaei Kl, Foster PS: Comparative Roles of lL-4, lL-13, and lL-4R{alpha} in Dendritic Cell Maturation and CD4+ Th2 Cell Function. J lmmunol 2007;178:219-227.
17. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G: Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993;12:2663-2670.
18. Murata T, Taguchi J, Puri RK, Mohri H: Sharing of receptor subunits and signal transduction pathway between the lL-4 and lL-13 receptor system. lnt J Hematol 1999;69:13-20.
19. Mueller TD, Zhang JL, Sebald W, Duschl A: Structure, binding, and antagonists in the lL-4/lL-13 receptor system. Biochim Biophys Acta 2002;1592:237-250.
20. Fukuda K, Fujitsu Y, Kumagai N, Nishida T: Characterization of the lnterleukin-4 Receptor Complex in Human Corneal Fibroblasts. lnvest Opthalmol Vis Sci 2002;43:183-188.
21. Lindqvist C, Lundstrom H, Oker-Blom C, Akerman KE: Enhanced lL-4-mediated D10.G4.1 proliferation with suboptimal concentrations of anti-lL-4 receptor monoclonal antibodies. J lmmunol 1993;150:394-398.
22. Beckmann MP, Schooley KA, Gallis B, Vanden Bos T, Friend D, Alpert AR, Raunio R, Prickett KS, Baker PE, Park LS: Monoclonal antibodies block murine lL-4 receptor function. J lmmunol 1990;144:4212-4217.
23. Holtzman MJ: Drug Development for Asthma. Am J Respir Cell Mol Biol 2003;29:163-171.
24. Maliszewski CR, Sato TA, Vanden Bos T, Beckmann MP, Grabstein KH: lnduction of B cell activities by interleukin 4 is inhibited by a receptor-specific monoclonal antibody in vitro. Eur J lmmunol 1990;20:1735-1740.
25. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D: Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:1-8.
26. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334:1697-702.
27. Heaney ML, Golde DW: Soluble receptors in human disease. J Leukoc Biol 1998;64:135-146.
28. Ahmed N, Dhanapala P, Sadli N, Barrow CJ, Suphioglu C: Mimtags: The use of phage display technology to produce novel protein-specific probes. J lmmunol Methods 2014;405:121-129.
29. Thomas P, Smart TG: HEK293 cell line: A vehicle for the expression of recombinant proteins. J Pharmacol Toxicol Methods 2005;51:187-200.
30. Tindemans I, Serafini N, Di Santo JP, Hendriks RW: GATA-3 function in innate and adaptive immunity Immunity 2014;41:191-206.
31. He JS, Narayanan S, Subramaniam S, Ho WQ, Lafaille JJ, Curotto de Lafaille MA: Biology of IgE production: IgE cell differentiation and memory of IgE responses. Curr Top Microbiol Immunol 2015;388:1-19.
32. Oh CK, Geba GP, Molfino N: Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19:46-54.
33. Valenta R, Campana R, Marth K, van Hage M: Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. J Intern Med 2012;272:144-157.
34. Moverare R, Elfman L, Vesterinen E, Metso T, Haahtela T: Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy 2002;57:423-430.
35. Boguniewicz M, Leung DYM: Targeted therapy for allergic diseases: At the intersection of cutting-edge science and clinical practice. J Allergy Clin Immunol 2015;135:354-356.
36. Holgate ST: New strategies with anti-IgE in allergic diseases. World Allergy Organ J 2014;7:17.
37. Keegan AD, Beckmann MP, Park LS, Paul WE: The IL-4 receptor: biochemical characterization of IL-4-binding molecules in a T cell line expressing large numbers of receptors. J Immunol 1991;146:2272-2279.
38. Pande J, Szewczyk MM, Grover AK: Phage display: concept, innovations, applications and future. Biotechnol Adv 2010;28:849-858.
39. Paschke M: Phage display systems and their applications. Appl Microbiol Biotechnol 2006;70:2-11.
40. Sidhu SS: Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol 2000;11:610-616.
41. Newton J, Deutscher S: Phage Peptide Display; in Semmler W, Schwaiger M (eds): Molecular Imaging II. Springer, Berlin Heidelberg, 2008, pp 145-163.
42. Smith GP, Petrenko VA: Phage Display. Chem Rev 1997;97:391-410.
43. Irving MB, Pan O, Scott JK: Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics. Curr Opin Chem Biol 2001;5:314-324.
44. Bottger V, Bottger A: Epitope mapping using phage display peptide libraries. Methods Mol Biol 2009;524:181-201.
45. Wang LF, Yu M: Epitope mapping using phage-display random fragment libraries. Methods Mol Biol 2009;524:315-332.
46. Rowley MJ, O'Connor K, Wijeyewickrema L: Phage display for epitope determination: a paradigm for identifying receptor-ligand interactions. Biotechnol Annu Rev 2004;10:151-188.
47. Huang J, Honda W: CED: a conformational epitope database. BMC Immunol 2006;7:7.
48. Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG, Gallop MA: Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc Natl Acad Sci USA 1992;89:5393-5397.
49. Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, Hudson E, Resau J, Gross M, Vande Woude GF, Hay R, Cao B: Identification of a met-binding peptide from a phage display library. Clin Cancer Res 2007;13:6049-6055.
50. D'Amato G, Liccardi G, Noschese P, Salzillo A, D'Amato M, Cazzola M: Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets Inflamm Allergy 2004;3:227-229.
51. van Odijk J, Ahlstedt S, Bengtsson U, Hulthen L, Borres MP: Specific IgE antibodies to peanut in western Sweden-has the occurrence of peanut allergy increased without an increase in consumption? Allergy 2001;56:573-577.
52. van Odijk J, Bengtsson U, Borres MP, Hulthen L, Ahlstedt S: Specific immunoglobulin E antibodies to peanut over time in relation to peanut intake, symptoms and age. Pediatr Allergy Immunol 2004;15:442-448.
53. Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG, Thomas D, Saban R, Jardieu P: Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107:308-312.
54. Mason JM: Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem 2010;2:1813-1822.
55. Sillerud LO, Larson RS: Design and Structure of Peptide and Peptidomimetic Antagonists of Protein-Protein Interaction. Curr Protein Pept Sci 2005;6:151-169.
56. Molek P, Strukelj B, Bratkovic T: Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors. Molecules 2011;16:857-887.